Search results for "Osteoblast"

showing 10 items of 152 documents

Isopropanolic Cimicifuga racemosa is favorable on bone markers but neutral on an osteoblastic cell line

2009

Postmenopausal women treated with an isopropanolic extract of Cimicifuga racemosa underwent a decrease in the urinary concentration of N-telopeptides, a marker of bone resorption, and an increase in alkaline phosphatase, a marker of bone formation, at the third month of therapy. Serum from treated women did not modify the activity of alkaline phosphatase or the expression of three genes, runt-related transcription factor-2 (Runx-2), alkaline phosphatase, and osteocalcin, when added to the MC3T3-E1 osteoblastic cell line.

Cimicifugamedicine.medical_specialtyOsteocalcinCore Binding Factor Alpha 1 SubunitOsteoblastic cellBone and BonesCollagen Type IBone resorptionCell Line2-PropanolMiceOsteogenesisInternal medicinemedicineAnimalsHumansProspective StudiesBone ResorptionOsteoblastsbiologyPlant Extractsbusiness.industryCimicifuga racemosaBone markersObstetrics and GynecologyOsteoblastAlkaline PhosphatasePostmenopauseEndocrinologymedicine.anatomical_structureReproductive MedicineCell cultureOsteocalcinbiology.proteinAlkaline phosphataseFemalePeptidesbusinessBiomarkersPhytotherapyFertility and Sterility
researchProduct

Terpenoid treatment in osteoporosis: this is where we have come in research.

2021

Lower bone resistance to load is due to the imbalance of bone homeostasis, where excessive bone resorption, compared with bone formation, determines a progressive osteopenia, leading to a high risk of fractures and consequent pain and functional limitations. Terpenoids, with their activities against bone resorption, have recently received increased attention from researchers. They are potentially more suitable for long-term use compared with traditional therapeutics. In this review of the literature of the past 5 years, we provide comprehensive information on terpenoids, with their anti-osteoporotic effects, highlighting molecular mechanisms that are often in epigenetic key and a possible p…

Endocrinology Diabetes and MetabolismOsteoporosisBioinformaticsBone resorptionBone and BonesFractures BoneEndocrinologyOsteoclastterpenoidsSettore BIO/13 - Biologia ApplicataSettore BIO/10 - Biochimicamedicinebone erosive diseasesHumansBone formationBone ResorptionProgressive osteopeniaepigeneticsbusiness.industryTerpenesOsteoporosis preventionOsteoblastmedicine.diseaseSettore BIO/18 - Geneticamedicine.anatomical_structureosteoclastosteoblastOsteoporosisbusinessTrends in endocrinology and metabolism: TEM
researchProduct

Non-flavonoid polyphenols in osteoporosis: preclinical evidence

2021

The development of progressive osteopenia and osteoporosis (OP) is due to the imbalance between bone resorption and bone formation, determining a lower bone resistance, major risks of fractures, with consequent pain and functional limitations. Flavonoids, a class of polyphenols, have been extensively studied for their therapeutic activities against bone resorption, but less attention has been given to a whole series of molecules belonging to the polyphenolic compounds. However, these classes have begun to be studied for the treatment of OP. In this systematic review, comprehensive information is provided on non-flavonoid polyphenolic compounds, and we highlight pathways implicated in the ac…

Endocrinology Diabetes and MetabolismOsteoporosisFlavonoid030209 endocrinology & metabolismBioinformaticsBone resorption03 medical and health sciences0302 clinical medicineEndocrinologypolyphenolic compoundsSettore BIO/13 - Biologia ApplicataOsteogenesisSettore BIO/10 - Biochimicabone erosive diseasesHumansMedicineBone formationBone ResorptionProgressive osteopeniaFlavonoidschemistry.chemical_classificationepigeneticsbusiness.industryPolyphenolsfood and beveragesmedicine.diseaseSettore BIO/18 - GeneticachemistryPolyphenolosteoclastosteoblastOsteoporosisbusinessTrends in Endocrinology & Metabolism
researchProduct

Flavonoids in Bone Erosive Diseases: Perspectives in Osteoporosis Treatment

2020

Imbalance of bone homeostasis, with excessive bone resorption compared with bone formation, leads to the development of progressive osteopenia leading to lower bone resistance to load, with consequent pain and functional limitations. Phytochemicals with therapeutic and preventive effects against bone resorption have recently received increasing attention since they are potentially more suitable for long-term use than traditional therapeutic chemical compounds. In this systematic review of the literature of the past 5 years, comprehensive information is provided on flavonoids with potential antiresorption and pro-osteogenic effects. It aims to highlight the molecular mechanisms of these mole…

Endocrinology Diabetes and MetabolismOsteoporosisOsteoclasts030209 endocrinology & metabolismBioinformaticsBone resorption03 medical and health sciences0302 clinical medicineEndocrinologyOsteoclastSettore BIO/13 - Biologia ApplicataSettore BIO/10 - BiochimicaOsteoporosis treatmentbone erosive diseasesMedicineAnimalsHumansEpigeneticsProgressive osteopeniaOsteoblastsbusiness.industrySettore BIO/16 - Anatomia UmanaOsteoblastmedicine.diseaseosteoporosisSettore BIO/18 - Geneticamedicine.anatomical_structureflavonoidsosteoclastosteoblastbusinessHomeostasisepigenetic
researchProduct

Potential Anti-Metastatic Role of the Novel miR-CT3 in Tumor Angiogenesis and Osteosarcoma Invasion

2022

Osteosarcoma (OS) is the most common primary bone tumor mainly occurring in young adults and derived from primitive bone-forming mesenchyme. OS develops in an intricate tumor microenvironment (TME) where cellular function regulated by microRNAs (miRNAs) may affect communication between OS cells and the surrounding TME. Therefore, miRNAs are considered potential therapeutic targets in cancer and one of the goals of research is to accurately define a specific signature of a miRNAs, which could reflect the phenotype of a particular tumor, such as OS. Through NGS approach, we previously found a specific molecular profile of miRNAs in OS and discovered 8 novel miRNAs. Among these, we deepen our …

Epithelial-Mesenchymal TransitionQH301-705.5MAP Kinase Signaling SystemEMT proteinBone NeoplasmsArticleCatalysisCell LineInorganic ChemistryCell Line TumorHuman Umbilical Vein Endothelial CellsmetastasisHumansNeoplasm InvasivenessBiology (General)Physical and Theoretical ChemistryQD1-999Molecular BiologySpectroscopyOsteosarcomaOsteoblastsmicroRNANeovascularization PathologicOrganic ChemistryEMT proteinstumor angiogenesisGeneral MedicinemicroRNAsComputer Science ApplicationsGene Expression Regulation NeoplasticChemistryosteosarcoma; microRNAs; tumor angiogenesis; metastasis; EMT proteinsmetastasitumor angiogenesiInternational Journal of Molecular Sciences
researchProduct

Lrp4, a Novel Receptor for Dickkopf 1 and Sclerostin, Is Expressed by Osteoblasts and Regulates Bone Growth and Turnover In Vivo

2009

Lrp4 is a multifunctional member of the low density lipoprotein-receptor gene family and a modulator of extracellular cell signaling pathways in development. For example, Lrp4 binds Wise, a secreted Wnt modulator and BMP antagonist. Lrp4 shares structural elements within the extracellular ligand binding domain with Lrp5 and Lrp6, two established Wnt co-receptors with important roles in osteogenesis. Sclerostin is a potent osteocyte secreted inhibitor of bone formation that directly binds Lrp5 and Lrp6 and modulates both BMP and Wnt signaling. The anti-osteogenic effect of sclerostin is thought to be mediated mainly by inhibition of Wnt signaling through Lrp5/6 within osteoblasts. Dickkopf1 …

Genetic Markersmusculoskeletal diseasesmedicine.medical_specialtylcsh:MedicineBiologyBone morphogenetic proteinBone and BonesCell LineMicechemistry.chemical_compoundInternal medicineBiochemistry/Cell Signaling and Trafficking StructuresmedicineAnimalsHumanslcsh:ScienceLDL-Receptor Related ProteinsAdaptor Proteins Signal TransducingGlycoproteinsBone growthBone DevelopmentOsteoblastsMultidisciplinarylcsh:RWnt signaling pathwayLRP6Rheumatology/Bone and Mineral MetabolismLRP5OsteoblastPhenotypemedicine.anatomical_structureEndocrinologyGene Expression RegulationReceptors LDLGenetics and Genomics/Disease ModelschemistryOsteocyteBone Morphogenetic ProteinsIntercellular Signaling Peptides and ProteinsSclerostinlcsh:QSignal TransductionResearch ArticlePLoS ONE
researchProduct

Cdc42 in osterix-expressing cells alters osteoblast behavior and myeloid lineage commitment

2021

Osteoblasts are not only responsible for bone formation. They also support hematopoiesis. This requires responding to cues originating from several signaling pathways, a task performed by Rho GTPases. We therefore examined several transgenic mouse models and used inhibitors of Cdc42 in vitro. Deletion of Cdc42 in vivo using the Osterix promoter suppressed osteoblast function, while its deletion in differentiating osteoblasts using the Collagen-a1(I) promoter decreased osteoblast numbers. In both cases, bone mineral density diminished confirming the importance of Cdc42. Evaluation of hematopoiesis revealed that deletion of Cdc42 using the Osterix, but not the Collagen-a1(I) promoter increase…

Genetically modified mousemusculoskeletal diseasesOsteoblastsHistologyMyeloidStromal cellPhysiologyChemistryEndocrinology Diabetes and MetabolismCell DifferentiationOsteoblastmacromolecular substancesBone and BonesCell biologyMiceHaematopoiesismedicine.anatomical_structureOsteogenesismedicineAnimalsCell LineageMyelopoiesisBone marrowSignal transduction
researchProduct

Inorganic Polyphosphate in Human Osteoblast-like Cells

1998

Significant amounts of inorganic polyphosphates and of polyphosphate-degrading exopolyphosphatase activity were detected in human mandibular-derived osteoblast-like cells. The amount of both soluble and insoluble long-chain polyphosphate in unstimulated osteoblast-like cells was higher than in human gingival cells, erythrocytes, peripheral blood mononuclear cells, and human blood plasma. The cellular content of polyphosphate in osteoblast-like cells strongly decreased after a combined treatment of the cells with the stimulators of osteoblast proliferation and differentiation, dexamethasone, beta-glycerophosphate, epidermal growth factor, and ascorbic acid. The amount of soluble long-chain p…

HL60Endocrinology Diabetes and MetabolismHL-60 CellsMandibleBiologyDexamethasonechemistry.chemical_compoundCalcitriolPolyphosphatesEpidermal growth factormedicineAnimalsHumansOrthopedics and Sports MedicinePyrophosphatasesCells CulturedExopolyphosphataseOsteoblastsDiphosphonatesEpidermal Growth FactorPolyphosphateCell DifferentiationEtidronic AcidOsteoblastAlkaline PhosphataseAscorbic acidAcid Anhydride HydrolasesRatsInorganic Pyrophosphatasemedicine.anatomical_structureSolubilitychemistryBiochemistryCell cultureGlycerophosphatesAlkaline phosphataseCell DivisionJournal of Bone and Mineral Research
researchProduct

Epidermal IL-17A leads to bone loss through inhibition of osteoblast differentiation

2012

The AP-1 transcription factor family is a central regulator of skin and bone homeostasis. We have previously shown that specific deletion of JunB/AP-1 in epidermis (JunBmice) results in skin inflammation,myeloproliferative disease, lupus-like disease and osteopenia. While upregulation of serum IL-6 and G-CSF are observed in this model, genetic deletion of these cytokines does not rescue osteopenia in JunB mice. Thus, we carried out a screen for other cytokines that are regulated by the loss of JunB in the epidermis. We have identified IL-17A as a cytokine expressed in JunB epidermis in vivo, and hypothesize that IL-17A leads to osteopenia in JunBmice. To test this,we carried out osteoblast …

HistologyEpidermis (botany)PhysiologyJUNBEndocrinology Diabetes and Metabolismmedicine.medical_treatmentInflammationOsteoblastBiologyCytokinemedicine.anatomical_structureDownregulation and upregulationOsteoclastmedicineCancer researchCytotoxic T cellmedicine.symptomBone
researchProduct

Activation of Human Osteoblasts via Different Bovine Bone Substitute Materials With and Without Injectable Platelet Rich Fibrin in vitro

2021

IntroductionThe aim of the in vitro study was to compare the effect of four bovine bone substitute materials (XBSM) with and without injectable platelet-reach fibrin for viability and metabolic activity of human osteoblasts (HOB) as well as expression of alkaline phosphatase (ALP), bone morphogenetic protein 2 (BMP-2), and osteonectin (OCN).Materials and MethodsCerabone® (CB), Bio-Oss® (BO), Creos Xenogain® (CX) and MinerOss® X (MO) ± i-PRF were incubated with HOB. At day 3, 7, and 10, cell viability and metabolic activity as well as expression of ALP, OCN, and BMP-2, was examined.ResultsFor non-i-PRF groups, the highest values concerning viability were seen for CB at all time points. Pre-t…

Histologyplatelet rich fibrin (PRF)proliferationlcsh:BiotechnologyBiomedical EngineeringBioengineering02 engineering and technologyBone morphogenetic protein 2vitalityFibrinAndrology03 medical and health sciences0302 clinical medicinelcsh:TP248.13-248.65medicineViability assaybovine boneOriginal ResearchbiologyChemistryBioengineering and Biotechnologyin vitroOsteoblastbone substitute030206 dentistry021001 nanoscience & nanotechnologydigestive system diseasesPlatelet-rich fibrinIn vitroPCRmedicine.anatomical_structureosteoblastbiology.proteinAlkaline phosphataseOsteonectin0210 nano-technologyBiotechnologyFrontiers in Bioengineering and Biotechnology
researchProduct